Literature DB >> 6186519

Suppressor mechanisms in tumor immunity.

G T Nepom, I Hellström, K E Hellström.   

Abstract

There are many parallels between T cell-mediated suppression of tumor immunity and suppression of immune responses to haptens and polypeptides. We propose a cell interaction model which takes this into account and outlines a regulatory pathway for suppression of immunity to tumor antigens. Free antigen or antigen/antibody complexes trigger an inducer T cell subset, Tsi, which is tumor-specific. This cell activates a non-immune T cell population, pre Tse, to generate effector suppressor cells, Tse. The Tse are specific for either the idiotype of Tsi or for antigen complexed with a soluble factor made by the Tsi, but the suppression they mediate is antigenically nonspecific. Tumor antigen-specific suppressor factors, TsF, play a major role in the communication between different suppressor cells. Characterization of polyclonal and monoclonal factors produced by Tsi, called TsFi, indicates that they both bind to tumor antigen and contain tumor-specific (idiotypic?) determinants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186519     DOI: 10.1007/bf01955286

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  81 in total

1.  Tolerance and contact sensitivity to DNFB in mice. VI. Inhibition of afferent sensitivity by suppressor T cells in adoptive tolerance.

Authors:  J W Moorhead
Journal:  J Immunol       Date:  1976-09       Impact factor: 5.422

Review 2.  T cell control of antibody production.

Authors:  R K Gershon
Journal:  Contemp Top Immunobiol       Date:  1974

3.  Proceedings: Proposed mechanisms by which autochthonous neoplasms escape immune rejection.

Authors:  J H Coggin; K R Ambrose; P J Dierlam; N G Anderson
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

4.  Correlation between immune complexes and prognostic factors in Hodgkin's disease.

Authors:  P L Amlot; B Pussell; J M Slaney; B D Williams
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

5.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

6.  Specific anti-tumor responses of cultured immune spleen cells III. Further characterization of cells which synthesize factors with blocking and antiserum-dependent cellular cytotoxic (ADC) activities.

Authors:  K Nelson; S B Pollack; K E Hellström
Journal:  Int J Cancer       Date:  1975-10-15       Impact factor: 7.396

7.  Evidence that tumor antigens enhance tumor growth in vivo by interacting with a radiosensitive (suppressor?) cell population.

Authors:  K E Hellström; I Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

8.  Hapten-coupled monoclonal anti-I-A antibodies provide a first signal for the induction of suppression.

Authors:  J S Bromberg; J T Nepom; B Benacerraf; M I Greene
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

9.  T cell subset interactions in the regulation of syngeneic tumor immunity.

Authors:  L L Perry; M I Greene
Journal:  Fed Proc       Date:  1981-01

10.  In vivo effects of antibodies to immune response gene products. I. Haplotype-specific suppression of humoral immune responses with a monoclonal anti-I-A.

Authors:  J T Rosenbaum; N E Adelman; H O McDevitt
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more
  9 in total

1.  Cellular requirements for the suppression of leucocyte adherence inhibition reactions by serum factors from tumour-bearing mice.

Authors:  V K Kuchroo; W J Halliday
Journal:  Immunology       Date:  1986-04       Impact factor: 7.397

2.  Cross-reactive variable-region associated epitopes of human IgG1 lambda paraprotein detected by a monoclonal antibody panel.

Authors:  L C Walker; S Dhut; W M Gregory; J A Habeshaw
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

Review 3.  Anti-idiotypic antibodies and the induction of specific tumor immunity.

Authors:  G T Nepom; K E Hellström
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Serial studies of autologous antibody reactivity to squamous cell carcinoma of the head and neck.

Authors:  D R Vlock; B Arnold; J Humpierres; D R Schwartz; S R Baker; C J Krause; N Swanson; T E Carey
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice.

Authors:  G T Nepom; K A Nelson; S L Holbeck; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

7.  Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

Authors:  C D Estin; U S Stevenson; G D Plowman; S L Hu; P Sridhar; I Hellström; J P Brown; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

Review 8.  Immune surveillance and natural resistance: an evaluation.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice.

Authors:  R A De Weger; B Wilbrink; R M Moberts; D Mans; R Oskam; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.